Literature DB >> 14598687

[Two-week administration of low-dose Hachimi-jio-gan (Ba-Wei Di-Huang-Wan) for patients with benign prostatic hyperplasia].

Koji Yoshimura1, Akito Terai, Yoichi Arai.   

Abstract

We evaluated the efficacy and side effects of two-week administration of low-dose "Hachimi-jio-gan (Ba-Wei Di-Huang-Wan)" for 41 patients with benign prostatic hyperplasia and searched for any predictors of good response to this agent. Although two of the 41 patients could not finish administration due to epigastric discomfort, there were no other side effects. "Hachimi-jio-gan" significantly reduced scores of emptying, weak stream, total score and quality of life score according to the International Prostate Symptom Score, although the degree of reduction was inferior to that induced by tamsulosin administration. "Hachimi-jio-gan" significantly improved max flow rate, and the degree of this improvement was superior to that induced by tamsulosin administration. Approximately 40% of patients were good responders to "Hachimi-jio-gan" therapy. Severe sensation of incomplete emptying was a predictor of good response.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598687

Source DB:  PubMed          Journal:  Hinyokika Kiyo        ISSN: 0018-1994


  2 in total

1.  Effects of Hachimijiogan, a Kampo powder, on epididymidis sperm characteristics in healthy male rats.

Authors:  Yuying Wang; Chiaki Murayama; Seiwa Michihara; Toru R Saito; Hisayoshi Norimoto
Journal:  Reprod Med Biol       Date:  2014-08-15

2.  Combination therapy with tamsulosin and traditional herbal medicine for lower urinary tract symptoms due to benign prostatic hyperplasia: A double-blinded, randomized, pilot clinical trial.

Authors:  Chung Lyul Lee; Hyeun-Kyoo Shin; Ji Yong Lee; Ojin Kwon; Chang-Seob Seo; Ae-Ran Kim; Bok-Nam Seo; Seung Woo Yang; Ki Hak Song; Jae Sung Lim; Jong Mok Park; Yong Gil Na; Ju Hyun Shin
Journal:  Int J Urol       Date:  2022-03-16       Impact factor: 2.896

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.